# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from...
Citigroup analyst Patrick Donnelly maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $1...
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $139 to $146.
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target fro...